What is Remdesivir
Remdesivir is an investigational antiviral medication with a broad spectrum of in vitro activity against RNA viruses belonging to Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae families.
Although not FDA-approved, the FDA has issued an Emergency Use Authorization (EUA) allowing intravenous remdesivir to be used in hospitalized COVID-19 patients with severe disease, defined as a SpO2 of 94% or less on room air, requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Indications
- coronavirus disease 2019 (COVID-19)
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
This drug may also have activity against the following microorganisms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Side Effects
- atrial fibrillation
- constipation
- delirium
- diaphoresis
- diarrhea
- ecchymosis
- elevated hepatic enzymes
- headache
- hematuria
- hypernatremia
- hypotension
- infusion-related reactions
- nausea
- phlebitis
- rash
- shivering
- vomiting
Monitoring Parameters
- CBC with differential
- LFTs
- serum creatinine/BUN
- serum electrolytes
Contraindications
- breast-feeding
- dialysis
- hepatic disease
- infusion-related reactions
- pregnancy
- renal failure
- renal impairment
Interactions
- Atropine; Hyoscyamine; Phenobarbital; Scopolamine
- Belladonna Alkaloids; Ergotamine; Phenobarbital
- Carbamazepine
- Dexamethasone
- Eslicarbazepine
- Fosphenytoin
- Isoniazid, INH; Pyrazinamide, PZA; Rifampin
- Isoniazid, INH; Rifampin
- Omeprazole; Amoxicillin; Rifabutin
- Oxcarbazepine
- Phenobarbital
- Phenytoin
- Primidone
- Rifabutin
- Rifampin
- Rifapentine
- Rufinamide
- St. John’s Wort, Hypericum perforatum
